Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcadium Lithium PLC

BlackSky Technology

Kinross Gold

Lithium Americas Argentina Corp

Sabre

Sirius XM Holdings Inc

To understand the allure of buying the best stocks under $10, it's a good idea to go back to basics. A stock's price reflects how much you pay for one dollar of a company's earnings.

The 7 Best Under $10 Stocks to Buy in August 2024

Altimmune, Inc. (NASDAQ:ALT ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Seema Sheoran - Evercore Omari Baruti - Goldman Sachs William Wood - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call.

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

Weight loss treatments such as Ozempic, Wegovy, Mounjaro, and Zepbound are big players in the diabetes and obesity care markets. One risk of losing weight is shedding too much muscle mass.

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year

Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH)

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Pfizer

Roche Holding AG

Viking Therapeutics

The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight loss space.

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.

GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update.

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ: ALT) on behalf of long-term stockholders following a class action complaint that was filed against Altimmune on May 6, 2024 with a Class Period from December 1, 2023 to April 26, 2024. Our investigation concerns whether the board of directors of Altimmune have breached their fiduciary duties to the company.

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Terns Pharmaceuticals

Eli Lilly and Novo Nordisk will need to share the weight-loss drugs market someday. Altimmune's candidate looks like it could succeed where their medicines struggle.

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

Zura Bio Ltd

Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.

3 Undervalued Biotech Stocks With Breakout Potential

Grab Holdings Ltd

Jumia

Tired of watching your portfolio crawl along? Standard investment advice often includes diversifying into bland, safe bets.

Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio

GLP-1 medicines for obesity are all the rage these days. Viking Therapeutics' candidate has the edge in the speed of weight loss.

Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics

Albemarle

Duolingo

Cloudflare

NVIDIA

Pinduoduo Inc - ADR

Sezzle Inc

Investors looking for opportunities will always be interested in high-potential stocks capable of turning $5K into $50K. Realistically speaking, securing 10x returns is not particularly easy.

7 Bullish Stock Picks With the Potential to Turn $5K Into $50K

Arcutis Biotherapeutics

JetBlue Airways

SoundHound AI Inc

Trulieve Cannabis Corp.

XPeng

Savvy investors are discovering rewarding opportunities in some of the best stocks under $10 a share. Years ago, I found Advanced Micro Devices (NASDAQ: AMD ) at $10 a share and watched it rocket above $200 on the artificial intelligence (AI) boom.

The 7 Best Under $10 Stocks to Buy in July 2024

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89388&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89367&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89267&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89275&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit

FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89246&wire=1 or contact Joseph E. Levi, Esq.

ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89254&wire=1 or contact Joseph E. Levi, Esq.

Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights – ALT

NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89171&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)

NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89176&wire=1 or contact Joseph E. Levi, Esq.

News for Altimmune Stock (ALT)